Patents by Inventor Philip R. Dormitzer
Philip R. Dormitzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220372115Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: ApplicationFiled: June 23, 2022Publication date: November 24, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Kurt SWANSON, Philip R. DORMITZER
-
Publication number: 20220340645Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: ApplicationFiled: June 23, 2022Publication date: October 27, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Kurt SWANSON, Philip R. DORMITZER
-
Publication number: 20220213177Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: ApplicationFiled: December 29, 2021Publication date: July 7, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Kurt SWANSON, Philip R. DORMITZER
-
Patent number: 11261239Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: GrantFiled: August 16, 2017Date of Patent: March 1, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Kurt Swanson, Philip R. Dormitzer
-
Publication number: 20200172600Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: ApplicationFiled: August 16, 2017Publication date: June 4, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Kurt Swanson, Philip R. Dormitzer
-
Patent number: 10287324Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.Type: GrantFiled: August 2, 2018Date of Patent: May 14, 2019Assignee: NOVARTIS AGInventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Patent number: 10192025Abstract: The present invention relates to the use of rotavirus particles for displaying a heterologous protein, alone or in complex with another molecule. The invention further relates to methods that employ these modified rotavirus particles to rapidly determine the structure of the heterologous protein or the complex using cryo-electron microscopy (cryo-EM). The invention also relates to a method of immunizing a patient, wherein said method comprises administering to the patient the modified rotavirus particles of the invention.Type: GrantFiled: July 8, 2014Date of Patent: January 29, 2019Assignee: Novartis AGInventors: Philip R. Dormitzer, Nikolaus Grigorieff, Stephen Harrison, Junhua Pan, Ethan Settembre
-
Publication number: 20190023746Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain.Type: ApplicationFiled: August 2, 2018Publication date: January 24, 2019Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Patent number: 10065994Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.Type: GrantFiled: November 19, 2015Date of Patent: September 4, 2018Assignee: Novartis AGInventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Patent number: 9744228Abstract: The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.Type: GrantFiled: April 7, 2011Date of Patent: August 29, 2017Assignee: Norvartis AGInventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Publication number: 20160222066Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain.Type: ApplicationFiled: November 19, 2015Publication date: August 4, 2016Inventors: Ethan Settembre, Angelica MEDINA-SELBY, Doris COIT, Philip R. DORMITZER
-
Publication number: 20160188790Abstract: The present invention relates to the use of rotavirus particles for displaying a heterologous protein, alone or in complex with another molecule. The invention further relates to methods that employ these modified rotavirus particles to rapidly determine the structure of the heterologous protein or the complex using cryo-electron microscopy (cryo-EM). The invention also relates to a method of immunising a patient, wherein said method comprises administering to the patient the modified rotavirus particles of the invention.Type: ApplicationFiled: July 8, 2014Publication date: June 30, 2016Inventors: Philip R. Dormitzer, Nikolaus Grigorieff, Stephen Harrison, Junhua Pan, Ethan Settembre
-
Patent number: 8685411Abstract: The present invention relates to novel recombinant polypeptide antigens that may comprise subunit vaccines against rotavirus infection. Further, the present invention relates to methods for use of said antigens in the diagnosis, treatment and prevention of rotavirus infection.Type: GrantFiled: January 3, 2007Date of Patent: April 1, 2014Assignees: Children's Medical Center Corporation, The Board of Trustees of the Leland Stanford Junior University, The United States of America as represented by the National Institutes of Health (NIH), The United States of America as represented by the Dept. of Health and Human Services (DHHS)Inventors: Philip R. Dormitzer, Stephen C. Harrison, Harry B. Greenberg, Joshua Yoder
-
Publication number: 20130273109Abstract: The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.Type: ApplicationFiled: April 7, 2011Publication date: October 17, 2013Applicant: NOVARTIS AGInventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Publication number: 20130171185Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.Type: ApplicationFiled: July 5, 2011Publication date: July 4, 2013Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Publication number: 20110305727Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: ApplicationFiled: July 15, 2010Publication date: December 15, 2011Applicant: Novartis AGInventors: Kurt Swanson, Philip R. Dormitzer